Insurers, Academics Protest High-Cost Drugs, Propose Solutions
by Shannon Firth
Contributing Writer
WASHINGTON -- Insurers and academics berated pharmaceutical companies for jacking up drug prices and suggested ways to alleviate the problem at the America's Health Insurance Plans National Health Policy Conference on Wednesday.
Much of the growth is due to a shift in prescribing higher cost drugs and price increases on existing drugs.
Diane Holder, president of UPMC Insurance Services Division in Pittsburgh, spoke of a friend and colleague who has hepatitis C but is not covered for expensive new curative treatments such as Sovaldi or Viekira Pak. The friend told Holder she was considering mortgaging her house to pay for drugs out-of-pocket.
Holder said she thought to herself, "It's just wrong ... there's a cure" for the disease.
Continue reading...
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment